Share This

Topics Comments

Cheung Kong VODone Limited Shenzhen International Holdings Limited Jiangxi Copper Company Limited REXLot Holdings Limited China Overseas Land & Investment Limited Chong Hing Bank Limited Agricultural Bank of China Limited Chow Tai Fook Jewellery Group Limited Capital VC Limited iShares A50 Standard Chartered Bank of Communications Bank of China China LotSynergy Holdings Limited agribank Agri Airlines Appl AUD Auto A Shares Brokers CAD fertilizer producers China Lottery Supermarket China Banks Communication Consumer China Econ Electricity China Finance China IT Petro Real Est China Resource Steel coal Commodity Beauty Drugs Enviro EURO Lang Simon Ting WongSir Andy Xie Expo Gambling Garment gas GBD Gold Gold Jew Gold mine Harbour Highways HK Apparel REITs Rentals HK Banks ETF HK Housing Market Real Est HK HK Stock iBond Infra Insure IPO jewel Mach Build Mat New Energy NZD Oil Paper Rare Earths Real Estate Market Food RMB Rising RMB RMB Bonds Shipbuilding Shipping Sports Stock Trend Taiwan Dollar (TWD) Textile Top 500 USD US Econ Util Water Yang Liu's 10 Stocks YEN Diary media Central Bank Monetary Policy Education Construction Emerging markets Nuclear power BillGross Cement HK retail logistics Swiss franc Social Security Fund Law Ka-Chung capital flow Financial and political policy Railway film Korean Won Roubini Faber Mobius
Topics Last reply time Nickname Content
BEIGENE, LTD. 2020-03-04T08:51 財經茄呢啡 百濟神州(6160)去年第四季及全年的收入分別達到5689萬元美元及4.28億元,分別按年減少3.03%及大增1.16倍。百濟的銷售收入達2.23億元,按年增長70.1%,主要來自ABRAXANE、瑞復美和維達莎在內地銷售。澤布替尼更在美國食品藥品管理局批准一周之內商業上市,百澤安則獲內地國家藥品監督管理局批准,計劃於本月內上市。
BEIGENE, LTD. 2020-03-04T08:51 財經茄呢啡 百濟神州(6160)將就安進(4332)的三款商業階段藥物開展商業化發展,並對其20款候選藥物進行臨床開發。公司在未來兩年,預計將推進八款藥物上市及臨床開發。
BEIGENE, LTD. 2020-03-04T08:51 財經茄呢啡 百濟(6160)年內的研發成本高達9.27億元,按年增長36.57%,主要與澤布替尼和百澤安關鍵臨床試驗、後期候選藥物註冊登記、商業化前生產和供應、臨床前項目擴展及員工股權獎勵支出增加有關。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.